Document:

Exhibit 10.43

 

[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

AMENDMENT #2 TO

LICENSE AGREEMENT

 

This Amendment #2 to License Agreement is entered into the 12th day of August, 2016, between UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, having an office at 910 Madison Avenue, Suite 827, Memphis, Tennessee 38163 (“UTRF”), and GTx, Inc., a Delaware corporation located at 175 Toyota Plaza, 7th Floor, Memphis, TN 38103 (“LICENSEE”).

 

BACKGROUND

 

THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (“UTRF”) and LICENSEE  entered into a License Agreement dated as of March 1, 2015 (“LICENSE AGREEMENT”) with respect to Selective Androgen Receptor Degraders (“SARDs”);

 

WHEREAS, the UT Contributors have developed new SARDs and disclosed the same to UTRF;

 

WHEREAS, UTRF and LICENSEE would like to amend and modify the LICENSE AGREEMENT to add the new material;

 

NOW THEREFORE, the parties agree that the LICENSE AGREEMENT is hereby amended, as follows:

 

APPENDIX A. Appendix A is hereby deleted in its entirety and Appendix A, attached hereto and made a part hereof, is substituted in lieu thereof.

 

ALL OTHER PROVISIONS shall remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the date first  written above.

 

	
UNIVERSITY OF TENNESSEE
    	
GTx, INC.
    
	
RESEARCH FOUNDATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: 
    	
/s/ Richard Magid
    	
 
    	
By: 
    	
/s/ Henry P. Doggrell
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name: 
    	
Richard Magid
    	
 
    	
Name: 
    	
Henry P. Doggrell
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title: 
    	
Vice President
    	
 
    	
Title: 
    	
Vice President, Chief Legal Officer
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
August 15, 2016
    	
 
    	
Date: 
    	
August 15, 2016
    

 

 

APPENDIX A to LICENSE AGREEMENT between

 

UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

 

and GTx, Inc.

 

LICENSED PATENTS

 

[***] (two pages omitted)

 

[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

2Exhibit 10.44

 

[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

AMENDMENT #3 TO
 LICENSE AGREEMENT

 

This Amendment #3 to License Agreement is entered into the 6th day of April, 2017, between UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, having an office at 910 Madison Avenue, Suite 827, Memphis, Tennessee 38163 (“UTRF”), and GTx, Inc., a Delaware corporation located at 175 Toyota Plaza, 7th Floor, Memphis, TN 38103 (“LICENSEE”).

 

BACKGROUND

 

THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (“UTRF”) and LICENSEE entered into a License Agreement dated as of March 1, 2015 (“LICENSE AGREEMENT”) with respect to Selective Androgen Receptor Degraders (“SARDs”);

 

WHEREAS, the UT Contributors have developed new SARDs and disclosed the same to UTRF;

 

WHEREAS, UTRF and LICENSEE would like to amend and modify the LICENSE AGREEMENT to add the new material;

 

NOW THEREFORE, the parties agree that the LICENSE AGREEMENT is hereby amended, as follows:

 

DEFINITIONS. Article 1.7 is hereby deleted in its entirety, and the following is substituted in lieu thereof:

 

1.7 “Invention Disclosures” means UTRF file numbers [***], submitted to UTRF on [***], [***], submitted to UTRF on [***], [***], submitted to UTRF on [***], and [***], submitted to UTRF on [***].

 

APPENDIX A. Appendix A is hereby deleted in its entirety and Appendix A, attached hereto and made a part hereof, is substituted in lieu thereof.

 

ALL OTHER PROVISIONS shall remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the date first written above.

 

	
UNIVERSITY OF TENNESSEE
    	
GTx, INC.
    
	
RESEARCH FOUNDATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: 
    	
/s/ Richard Magid
    	
 
    	
By: 
    	
/s/ Henry P. Doggrell
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name: 
    	
Richard Magid
    	
 
    	
Name: 
    	
Henry P. Doggrell
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title: 
    	
Vice President
    	
 
    	
Title: 
    	
Vice President, Chief Legal Officer
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
April 7, 2017
    	
 
    	
Date: 
    	
April 7, 2017
    

 

1

 

APPENDIX A to LICENSE AGREEMENT between

 

UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

 

and GTx, Inc.

 

LICENSED PATENTS

 

[***] (two pages omitted)

 

[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

2Exhibit 10.45

 

[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

AMENDMENT #4 TO

LICENSE AGREEMENT

 

This Amendment #4 to License Agreement is entered into the 23rd day of October, 2018,  between UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, having an office at 910 Madison Avenue, Suite 827, Memphis, Tennessee 38163 (“UTRF”), and GTx, Inc., a Delaware corporation located at 175 Toyota Plaza, 7th Floor, Memphis, TN 38103 (“LICENSEE”).

 

BACKGROUND

 

THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (“UTRF”) and LICENSEE  entered into a License Agreement dated as of March 1, 2015 (“LICENSE AGREEMENT”) with respect to Selective Androgen Receptor Degraders (“SARDs”);

 

WHEREAS, the UT Contributors have developed new SARDs and disclosed the same to UTRF;

 

WHEREAS, UTRF and LICENSEE would like to amend and modify the LICENSE  AGREEMENT to add the new material;

 

NOW THEREFORE, the parties agree that the LICENSE AGREEMENT is hereby amended, as  follows:

 

DEFINITIONS. Article 1.7 is hereby deleted in its entirety, and the following is substituted in lieu thereof:

 

1.7 “Invention Disclosures” means UTRF file numbers [***], submitted to UTRF on [***], [***], submitted to UTRF on [***], [***], submitted to UTRF on [***], [***], submitted to UTRF on [***], and [***], submitted to UTRF on [***].

 

APPENDIX A. Appendix A is hereby deleted in its entirety and Appendix A, attached hereto and made a part hereof, is substituted in lieu thereof.

 

ALL OTHER PROVISIONS shall remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the date first  written above.

 

	
UNIVERSITY OF TENNESSEE
    	
GTx, INC.
    
	
RESEARCH FOUNDATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: 
    	
/s/Richard Magid
    	
 
    	
By:
    	
/s/ Henry P. Doggrell
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name: 
    	
Richard Magid
    	
 
    	
Name: 
    	
Henry P. Doggrell
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title: 
    	
Vice President
    	
 
    	
Title: 
    	
Vice President, Chief Legal Officer
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
November 15, 2018
    	
 
    	
Date: 
    	
November 13, 2018
    

 

 

APPENDIX A to LICENSE AGREEMENT between

 

UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

 

and GTx, Inc.

 

LICENSED PATENTS

 

	
[***]
    	
[***]
    	
[***]
    	
[***]
    	
[***]
    	
[***]
    	
[***]
    

 

(three pages omitted)

 

[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 4.11

 

Amendment No. 7

to

Gilat Satellite Networks Ltd. 2008 Share Incentive Plan

(the “Plan”)

Dated August 6, 2018

 

The terms of the Plan are hereby revised as follows:

	
-

	
In Section 6(a) of the Plan, the first sentence is hereby deleted and replaced by the following wording:

“Subject to the provisions of Section 6(b), the maximum number of Ordinary Shares that may be issued under the Plan is 6,104,000 in a fungible pool of Ordinary Shares”.

	
-

	
All other terms shall remain unchanged.

 

Amendment No. 8

to

Gilat Satellite Networks Ltd. 2008 Share Incentive Plan

(the “Plan”)

Dated February 11, 2019

 

The terms of the Plan are hereby revised as follows:

 

In Section 6(a) of the Plan, the first sentence is hereby deleted and replaced with the following wording:

“Subject to the provisions of Section 6(b), the maximum number of Ordinary Shares that may be issued under the Plan is 6,465,500 in a fungible pool of Ordinary Shares”.

All other terms shall remain unchanged.

Amendment No. 9

to

Gilat Satellite Networks Ltd. 2008 Share Incentive Plan

(the “Plan”)

Dated February 12, 2019

 

The terms of the Plan are hereby revised as follows:

	
A.

	
The following language will be added as Section 6(b1):

“In the event the Company declares a cash dividend to its shareholders and the distribution date of such cash dividend preceded the exercise of a Share Option, then the Exercise Price of each outstanding Share Option (whether vested or not) on the applicable distribution date of such cash dividend shall be automatically reduced by an amount equal to the cash dividend per Share distributed by the Company on such distribution date (the "Dividend Adjustment"); provided, however, that the Dividend Adjustment shall not apply to any cash dividend for which the Board resolves on the declaration date of such cash dividend not to apply the Dividend Adjustment.

 

To the extent required by applicable stock exchange regulations, no Share Options shall be exercised on a record date and ex-date, if earlier, of any stock dividend, other distribution of dividends, rights offering, stock split, reverse stock split or reduction of authorized share capital.”

	
B.

	
The following language will be added in section 7(d) after the words “bank cashier's check”:

“Notwithstanding, pursuant to Board resolution, payment may be made by a method whereby the Committee shall withhold a number of Shares otherwise deliverable to the Participant pursuant to the Option (in this Section 7(d) ("Net Exercise"), according to the following formula:

 

N = X(A-B)/A

Where:

“N” = the calculated number of Shares to be issued to the Participant upon exercise of the Option after rounding to the nearest whole number;

“X” = the number of Shares with respect to which the Option is exercised, according to the Participant's notice of exercise;

“A” = the higher between: (1) the closing price for a Share on the last trading day prior to the exercise date or (2) the limit price that the Participant has indicated when submitted the same-day sale instructions to a broker.

“B” = the exercise price per Share (as defined in the Participant’s applicable Award Agreement).”

All other terms shall remain unchanged.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]